| Ytd | -33.21% | |
| 1y | -23.13% |
| Open | 5.49 | Prev Close | 5.44 | Low | 5.41 | High | 5.51 | Mkt Cap | 57.95M |
| Vol | 4.54K | Avg Vol | 56.38K | EPS | -0.82 | P/E | -6.63 | Forward P/E | -1.19 |
| Beta | 1.47 | Short Ratio | 3.19 | Inst. Own | 15.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 6.10 | 200-d Avg | 6.05 | 1yr Est | 6.33 |
VRCA News
Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maint
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasda
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese pati
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zac
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026,
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcino
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free
LOS ANGELES--(BUSINESS WIRE)---- $VRCA--VRCA Investors Have the Opportunity to Join Investigation of
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investiga
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investiga
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative ex
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “th
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.